With increasing life expectancy in people with Cystic fibrosis (CF), the focus of clinical care has shifted to management and prevention of non-pulmonary comorbidities. CF related bone disease, defined by low bone mineral density (BMD), is prevalent across all age groups and acknowledges the increased fractures rates that negatively impact lung function and quality of life. Dual energy X-ray absorptiometry (DXA) measurement of bone mineral content (BMC) and "areal" BMD (aBMD) is recommended for identifying and monitoring bone health in children and adults due to its low cost, low radiation exposure, and widespread availability. Recent studies in children and adolescents with chronic illness focus on adjustment of BMC and aBMD measurements for height due to the effects of short stature and delayed maturation on bone size. Expanded reference databases for alternate imaging sites such as the ultradistal radius and hip present opportunities for research and long-term monitoring. As the two-dimensional nature of DXA imposes limitations, we highlight other imaging modalities including peripheral quantitative computed tomography QCT (pQCT), magnetic resonance imaging, and quantitative ultrasound (QUS). These tools, while primarily used in a research setting, can impart information on true volumetric bone density and bone microarchitecture as well as contribute to fracture assessment and prediction. Due to the high morbidity and mortality associated with vertebral and hip fracture, we will present on vertebral fracture assessment (VFA) in both children and adults as well as applied analyses including hip structural analysis (HSA), trabecular bone score (TBS), and fracture risk assessment (FRAX) for high risk groups. Questions remain on the future clinical applicability and accessibility of these assessment and prediction tools, longitudinal monitoring through adolescence and adulthood, and how outcome measures may guide bone modifying therapies.
Keywords: BMC, bone mineral content; BMD, bone mineral density; Bone disease; Bone mineral density; CF, Cystic Fibrosis; CFBD, Cystic fibrosis related bone disease; Cystic fibrosis; DXA, dual energy x-ray absorptiometry; Dual energy x-ray absorptiometry; FRAX, Fracture Risk Assessment Tool; Fracture; HAZ, height for age Z-score; HSA, Hip Structural Analysis; ISCD, International Society Clinical Densitometry; LS, lumbar spine; LSC, least significant change; MRI, magnetic resonance imaging; QUS, quantitative ultrasound; SOS, speed of sound; TBLH, total body less head; TBS, Trabecular Bone Score; UBPI, Ultrasound bone profile index; UD radius, Ultradistal radius; VFA, Vertebral Fracture Assessment; aBMD, areal bone mineral density; pQCT, peripheral quantitative computed tomography.
© 2021 The Authors.